Blood Donation--Immune Sequelae and Recruitment
NCT00005341 · Status: TERMINATED · Type: OBSERVATIONAL
Last updated 2024-03-12
Summary
To determine if there were immune sequelae related to the long-term donation of blood or blood products.
Conditions
- Blood Donors
- Blood Disease
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
University of New Mexico
lead OTHER
Eligibility
- Min Age
- 0 Years
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1992-02-29
- Completion
- 1997-01-31
More Related Trials
-
Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects
NCT03070561 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency
NCT03492710 ·Status: WITHDRAWN ·Phase: PHASE3
-
Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers
NCT03837093 ·Status: COMPLETED ·Phase: PHASE1
-
Role of Circulating Innate Lymphoid Cells in Allergic Disorders
NCT03069495 ·Status: TERMINATED
-
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995
NCT02082353 ·Status: UNKNOWN
-
Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections
NCT00004996 ·Status: COMPLETED
-
Itacitinib for Low Risk GVHD
NCT03846479 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
NCT02783482 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
NCT02234934 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome
NCT00001145 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Abatacept in IgG4-Related Disease
NCT03669861 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Vaccine Responses in PIDD Subjects
NCT05321407 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
NCT03203369 ·Status: TERMINATED ·Phase: PHASE1
-
Immune Globulin Subcutaenous (Human), 20%
NCT01412385 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
NCT05660421 ·Status: WITHDRAWN ·Phase: PHASE2
-
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
NCT00546871 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
NCT02810444 ·Status: COMPLETED ·Phase: PHASE3
-
Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib
NCT05095649 ·Status: RECRUITING ·Phase: PHASE2
-
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
NCT01175213 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
NCT00275613 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
NCT06990529 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
NCT06530004 ·Status: RECRUITING
-
A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease
NCT06413511 ·Status: WITHDRAWN ·Phase: PHASE1
-
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
NCT00072592 ·Status: COMPLETED ·Phase: PHASE1
-
Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment
NCT01359384 ·Status: UNKNOWN